<?xml version="1.0" encoding="UTF-8"?>
<ref id="B21">
 <label>21</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ready</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Farago</surname>
    <given-names>AF</given-names>
   </name>
   <name>
    <surname>de Braud</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Atmaca</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Hellmann</surname>
    <given-names>MD</given-names>
   </name>
   <name>
    <surname>Schneider</surname>
    <given-names>JG</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Third-Line Nivolumab Monotherapy in Recurrent Sclc: CheckMate 032</article-title>. 
  <source>J Thorac Oncol</source> (
  <year>2019</year>) 
  <volume>14</volume>(
  <issue>2</issue>):
  <page-range>237â€“44</page-range>. 
  <pub-id pub-id-type="doi">10.1016/j.jtho.2018.10.003</pub-id>
 </mixed-citation>
</ref>
